Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory DiseasesAuthor of the article:First-in-class bispecific antibody designed for mast cell elimination without the safety issues associated with current KIT therapeuticsPhase 1 single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of subcutaneous and intravenous SAB01 in healthy adultsTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountALAMEDA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today announced that the first cohort has been dosed in the first-in-human Phase 1 study of SAB01, a novel bispecific antibody designed to selectively deplete mast cells through co-engagement of KIT and Siglec-6.“This marks Santa Ana Bio’s transition into the clinic and opens a new approach to the treatment of mast cell-driven disease,” said Peter Emtage, founder and chief executive officer of Santa Ana Bio. “KIT-targeted antibodies drive rapid and deep responses in chronic urticaria, but KIT isn’t exclusive to mast cells, leading to toxicities from hitting other cell types, including hematopoietic stem cells and melanocytes. SAB01 was designed to uncouple mast cell depletion from broad KIT inhibition.”Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againSAB01 is a first-in-class bispecific antibody that simultaneously engages KIT and Siglec-6, a receptor pair co-expressed on mast cells and not found together on any other cell type. Avidity-driven co-engagement of both receptors, along with an extended half-life, restricts SAB01 activity to mast cells, selectively and durably depleting them while sparing other KIT-expressing cells.“The initiation of this Phase 1 healthy volunteer study builds on extensive preclinical work supporting SAB01’s conditional depletion of mast cells,” said Newman Yeilding, M.D., Chief Medical Officer of Santa Ana Bio. “The start of our Phase 1 study of SAB01 is the first step in bringing a truly selective and potentially safer mast cell targeted therapy to patients.”The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating subcutaneous and intravenous SAB01 in healthy adult participants. Fifty-six participants will be enrolled across six subcutaneous cohorts and one intravenous cohort of eight participants each, randomized 6:2 to SAB01 or placebo. Further cohorts may be enrolled to evaluate select dose levels based on emerging safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. For additional information on this trial (NCT07815561), please visit www.clinicaltrials.gov.Santa Ana Bio is a biotechnology company developing a pipeline of innovative therapeutics that leverage a multi-omics platform to advance precision medicines for autoimmune and inflammatory diseases. The company’s mission is to improve the lives of patients affected by a wide range of chronic and life-impacting diseases. Santa Ana is advancing a portfolio of innovative product candidates designed to address the biology underlying autoimmune and inflammatory conditions. For more information, visit www.santaana.bio and follow on LinkedIn.Neil Abdollahiannabdollahian@santaana.bioThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.